Both vatreptacog alfa and rFVIIa gave 93 % effective bleeding control at 12 h. Vatreptacog alfa was superior to rFVIIa in secondary efficacy outcomes , including the number of doses used to treat a bleed and sustained bleeding control 24-48 h after the first dose .